Pull to refresh
Logo
What Changed
Following Why Sign Up
FDA clears Protego's pivotal trial of PROT-001 for AL amyloidosis

FDA clears Protego's pivotal trial of PROT-001 for AL amyloidosis

New Capabilities

Oral light chain stabilizer moves to a Phase 2/3 study added to standard plasma cell therapy in newly diagnosed patients

October 19th, 2026: FDA clears IND

Overview

Updated Oct 25

The Food and Drug Administration cleared Protego Biopharma to start SHIELD-AL, a Phase 2/3 trial of PROT-001 in newly diagnosed lambda light chain AL amyloidosis. Protego says the study is planned to begin in the first quarter of 2027.

PROT-001 is an oral add-on to plasma cell-directed therapy, the current backbone of treatment. Those drugs target the cells that make misfolded light chains; PROT-001 binds the lambda light chains themselves to keep them from clumping in organs such as the heart. A gap in the field widened in 2026: anselamimab, a kappa-directed antibody, missed its overall endpoint in the phase 3 CARES trial and showed no benefit in lambda patients. Protego expects Phase 1 data in healthy volunteers at a medical meeting later in 2026.

Why it matters

If PROT-001 works, AL amyloidosis patients get the first therapy that stops protein misfolding itself, not just the cells that make faulty proteins.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$130M
Series B funding
Oversubscribed round closed in December 2025 to fund pivotal development.
Q1 2027
Planned SHIELD-AL start
Protego says the global Phase 2/3 study in newly diagnosed lambda patients is planned to begin in the first quarter of 2027.
~80%
Lambda light chain share
Lambda is the predominant light chain in AL amyloidosis; SHIELD-AL targets lambda patients.
599
Patients in retrospective study
The PRO-AL-001 retrospective study spanned 599 AL amyloidosis patients.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Brent J. Warner
Brent J. Warner
Chief Executive Officer, Protego Biopharma
Leading the company into pivotal development
 Jae B. Kim, MD
Jae B. Kim, MD
Chief Medical Officer
Appointed 2026; shepherding SHIELD-AL
JK
Jeffery Kelly
Co-founder; Scripps Research professor
Scientific founder behind PROT-001
 Chris Weyrer, MD, PhD
Chris Weyrer, MD, PhD
Principal at Vida Ventures; acting Chief Business Officer
Board seat at Protego

Organizations Involved

Protego Biopharma
Protego Biopharma
Clinical-stage biotechnology company
Lead candidate PROT-001 cleared for pivotal trial

San Diego clinical-stage biotech developing small molecules that stabilize protein folding to treat systemic amyloid diseases.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Cleared PROT-001 investigational new drug application

The US FDA cleared the investigational new drug application enabling Protego to start the SHIELD-AL pivotal study.

Timeline

2017 October 2026

8 events Latest: October 19th, 2026 · 3 weeks ago
Tap a bar to jump to that date

  1. FDA clears IND

    Latest Regulatory

    FDA clears investigational new drug application; SHIELD-AL pivotal study authorized.

  2. Phase 2/3 plans set

    Planning

    Company plans pivotal trial for AL amyloidosis in the second half of 2026.

  3. Anselamimab misses overall endpoint, helps kappa subgroup

    Clinical Trial

    The phase 3 CARES trial of anselamimab did not meet its primary endpoint in the overall population but cut the risk of death by 62% in patients with kappa light chain involvement. No benefit was seen in lambda patients.

  4. Linvoseltamab produces deep responses as single agent

    Clinical Trial

    In a phase I/II trial, the bispecific antibody linvoseltamab-gcpt produced a very good partial response or better in 100% of patients and normalized involved free light chains at a median of 2.1 weeks.

  5. Phase 1 completes

    Clinical Trial

    Phase 1 study in volunteers completes in Australia under NCT06981299.

  6. Series B raised

    Funding

    Oversubscribed $130M round closes, led by Novartis Venture Fund and Forbion.

  7. Phase 1 begins

    Clinical Trial

    First-in-human trial of PROT-001 starts in healthy volunteers in Australia.

  8. Protego founded

    Founding

    Protego Biopharma founded in San Diego to develop protein-stabilizing drugs for misfolding diseases.

Scenarios

1

Positive SHIELD-AL interim data; PROT-001 heads to FDA filing

Likely Resolves by Q2 2028

Discussed by: Protego leadership; BioPharma Dive analysis of the Series B

SHIELD-AL pairs PROT-001 with standard-of-care plasma cell therapy in newly diagnosed lambda AL amyloidosis patients. The company's stated goal of pursuing accelerated and full approval, plus the appointment of a regulatory-seasoned CMO, signal confidence. Positive interim results showing deeper or faster responses would make PROT-001 the first protein stabilizer approved for light chain amyloidosis.

2

SHIELD-AL enrollment or program hits a delay

Possible Resolves by Q2 2027

Discussed by: AdisInsight pipeline tracking; standard rare-disease trial timelines

Pivotal trials in rare diseases often lag on enrollment, especially with an add-on control. Any FDA clinical hold, supply problem or slow site activation would push the timeline past company guidance. Enrollment status on ClinicalTrials.gov is the clearest signal of a slip.

3

PROT-001 fails pivotal endpoint; program wound down

Uncertain Resolves by Q2 2029

Discussed by: Standard drug development risk; analysts noting limitations of current therapy

If the interim or final analysis shows no added benefit over standard of care alone, the add-on design would likely be discontinued. The company has framed PROT-001 as potentially paradigm-shifting; a miss would leave AL amyloidosis without its first stabilizer and raise questions about the chaperone approach in light chain disease.

4

A rival therapy reaches lambda patients before SHIELD-AL reads out

Possible Resolves by End of 2027

Discussed by: ASCO Post reporting on the 2026 CARES and linvoseltamab data

Anselamimab's survival benefit was confined to kappa light chain patients, leaving the lambda gap PROT-001 targets open. Linvoseltamab produced deep hematologic responses on its own. A regulatory win for either would reset the standard of care, or raise the bar SHIELD-AL has to clear, before Protego reports pivotal data.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2019

Tafamidis (Vyndamax) approval for transthyretin amyloidosis (2019)

Tafamidis, discovered by FoldRx and acquired by Pfizer, stabilized transthyretin to stop it misfolding and depositing in the heart. The FDA approved it as Vyndamax in 2019, the first drug for transthyretin amyloid cardiomyopathy.

Then

Became a blockbuster, generating billions in annual sales and changing care for a disease once seen as untreatable.

Now

Validated the chaperone concept that Protego's Jeffery Kelly helped build; tafamidis remains standard therapy.

Why this matters now

Vyndamax is the same mechanism class PROT-001 targets, but for transthyretin, not immunoglobulin light chains. Its commercial success set the template Kelly's newer company hopes to repeat.

January 2021

Daratumumab (Darzalex) approval for AL amyloidosis (2021)

Daratumumab, a plasma cell-depleting antibody, won FDA approval for AL amyloidosis in 2021 after the Andromeda trial showed it improved responses when added to chemotherapy.

Then

Became the backbone of AL amyloidosis care, giving patients a more effective option than earlier regimens.

Now

Established the standard of care PROT-001 is designed to complement, not replace.

Why this matters now

SHIELD-AL adds PROT-001 on top of this very backbone, testing whether protein stabilization yields deeper, faster responses than cell depletion alone.

Sources

(12)
+6
PR Newswire Protego Biopharma Springer BioPharma Dive Forbion VCBeat BioWorld Whiteford Research The ASCO Post PR Newswire Protego Biopharma Protego Biopharma